C73 - Multiple Sclerosis Therapy: Disease-modifying Treatment II
| Event Time: | Sunday May 5, 2019 3:30 pm to 5:30 pm |
| Topic(s): | MS and CNS Inflammatory Disease, Foundations in Clinical Neurology for APPs |
| Director(s): | John Rose MD, FAAN |
| Description: | The use of disease-modifying treatments (DMTs) in MS is one of the most rapidly evolving therapeutic areas in neurology. As new and arguably more effective treatments have become available, decision-making in regard to MS DMTs has become much more complex for both neurologists and people with MS. This course will review the mechanisms of action and the risk-benefit ratios of the DMTs and delve into different treatment paradigms, risk mitigation strategies, sequencing considerations, and shared decision making. This program complements Multiple Sclerosis Therapy: Disease-modifying Treatment I, but covers independent topics. |
| Completion Message: | Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropriate patient populations for the newer agents. |
| CME Credits: | 2 |
| Core Competencies: | Patient Care, Medical Knowledge, Practice-Based Learning and Improvement |
| Start/End Time | Title | Faculty |
|---|---|---|
| 3:30 PM - 3:35 PM | Introduction | John W. Rose MD, FAAN |
| 3:35 PM - 4:25 PM | DMTs: Importance of Age and Gender | Maria K. Houtchens MD |
| 4:25 PM - 4:30 PM | Questions and Answers | Maria K. Houtchens MD |
| 4:30 PM - 5:20 PM | Progressive MS Management and Treatment | M. Mateo Paz Soldan MD, PhD |
| 5:20 PM - 5:30 PM | Questions and Answers | M. Mateo Paz Soldan MD, PhD |
| Speaker | Disclosure |
|---|---|
| Maria K. Houtchens, MD | Dr. Houtchens has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme Sanofi, Teva Neurosciences, Biogen, Genentech. Dr. Houtchens has received research support from Genzyme Sanofi, Biogen, Serono. |
| M. Mateo Paz Soldan, MD, PhD | Dr. Paz Soldan has received research support from Biogen. |
| John W. Rose, MD, FAAN | Dr. Rose has received research support from National Multiple Sclerosis Society, Guthy Jackson Foundation, NIH, Friends of MS, Western Institute for Biomedical Research, and Biogen. |
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C247 -
What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders
Stephanie Nahas MD, FAAN |
|
C248 -
Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
Aaron Miller MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S56 -
MS Trials and Treatment
|
| 3:30 PM-4:30 PM |
|
C257 -
Education Blitz: Evolution of Autoimmune Neurology
Steven Vernino MD, PhD, FAAN |
|
C258 -
Education Blitz: Multiple Sclerosis
Stephen Krieger MD, FAAN |